# Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery

> **NCT01497444** · PHASE1 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 24 (actual)

## Conditions studied

- Kidney Cancer
- Liver Cancer

## Interventions

- **DRUG:** hypoxia-activated prodrug TH-302
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT01497444
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2016-01
- **Final completion:** 2019-11-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01497444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01497444, "Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01497444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*